Anti-Titin (IgG + IgA)

Optimal result: 0 – 10 Units

The Anti-Titin (IgG + IgA) biomarker, measured in Vibrant Wellness' Neural Zoomer Plus panel, assesses immune reactivity to titin, a giant protein critical for muscle elasticity and contraction. This test helps identify autoimmune responses targeting neuromuscular tissues, which may underlie conditions like myasthenia gravis and thymoma-associated syndromes.


What It Measures

The test detects IgG and IgA antibodies against titin, a structural protein in skeletal and cardiac muscle. Titin stabilizes sarcomeres during muscle contraction, and autoantibodies against it are often linked to neuromuscular junction dysfunction.


Clinical Relevance

Anti-Titin antibodies are associated with:

  • Myasthenia Gravis (MG):

    • Found in approximately 30% of generalized MG cases, particularly in patients with thymoma (a tumor of the thymus).

    • Associated with severe disease phenotypes and poorer response to acetylcholinesterase inhibitors.

  • Thymoma Screening:

    • The presence of Anti-Titin antibodies may prompt imaging (e.g., chest CT) to rule out thymic tumors.

  • Late-Onset MG:

    • More common in patients over 50, often without thymoma, but with higher rates of muscle-specific kinase (MuSK) antibodies.

The Anti-Titin (IgG + IgA) biomarker, measured in Vibrant Wellness' Neural Zoomer Plus panel, assesses immune reactivity to titin, a giant protein critical for muscle elasticity and contraction. This test helps identify autoimmune responses targeting neuromuscular tissues, which may underlie conditions like myasthenia gravis and thymoma-associated syndromes.


What It Measures

The test detects IgG and IgA antibodies against titin, a structural protein in skeletal and cardiac muscle. Titin stabilizes sarcomeres during muscle contraction, and autoantibodies against it are often linked to neuromuscular junction dysfunction.


Clinical Relevance

Anti-Titin antibodies are associated with:

  • Myasthenia Gravis (MG):

    • Found in approximately 30% of generalized MG cases, particularly in patients with thymoma (a tumor of the thymus).

    • Associated with severe disease phenotypes and poorer response to acetylcholinesterase inhibitors.

  • Thymoma Screening:

    • The presence of Anti-Titin antibodies may prompt imaging (e.g., chest CT) to rule out thymic tumors.

  • Late-Onset MG:

    • More common in patients over 50, often without thymoma, but with higher rates of muscle-specific kinase (MuSK) antibodies.


Interpretation of Results

  • Positive Result (High/Moderate Reactivity):

    • Suggests autoimmune targeting of muscle proteins.

    • Correlates with myasthenia gravis, thymoma, or other neuromuscular disorders.

    • Requires clinical confirmation (e.g., electromyography, acetylcholine receptor antibody testing).

  • Negative Result:

    • Reduces likelihood of titin-associated autoimmune myasthenia but does not exclude other neuromuscular conditions.


Testing Considerations

  • Panel Context: The Neural Zoomer Plus evaluates 48 neurological antigens, including titin, to map autoimmune contributors to symptoms like muscle weakness or fatigue.

  • Complementary Tests:

    • Anti-Acetylcholine Receptor Antibodies: Confirms MG diagnosis.

    • Chest Imaging: For thymoma detection.

  • Limitations:

    • Low titin antibody titers may occur in non-autoimmune conditions (e.g., aging, cardiac disease).

    • Results should be interpreted alongside symptoms and other biomarkers.


Conclusion

Anti-Titin (IgG + IgA) testing on the Neural Zoomer Plus aids in diagnosing autoimmune neuromuscular disorders, particularly myasthenia gravis with thymoma. While positive results guide targeted interventions (e.g., immunosuppression, thymectomy), clinical correlation remains essential.

Anti-Titin (IgG + IgA)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Anti-Titin (IgG + IgA) — 10,000+ markers explained
One Anti-Titin (IgG + IgA) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro